{"entity": "researcher", "timestamp": "2026-08-20T20:34:39.569Z", "family": "Johansson", "given": "Therese", "initials": "T", "orcid": "0000-0003-1043-7065", "affiliations": ["Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.", "Centre for Women's Mental Health during the Reproductive Lifespan-WoMHeR, Uppsala University, Uppsala, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/d4005242bc4c45f6a0899226560837f8.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/d4005242bc4c45f6a0899226560837f8"}}, "publications": [{"entity": "publication", "iuid": "dba782301a3f4893b2b439eac4f7445e", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/dba782301a3f4893b2b439eac4f7445e.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/dba782301a3f4893b2b439eac4f7445e"}}, "title": "Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial.", "authors": [{"family": "Johansson", "given": "Therese", "initials": "T", "orcid": "0000-0003-1043-7065", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/d4005242bc4c45f6a0899226560837f8.json"}}, {"family": "Karlsson", "given": "Torgny", "initials": "T"}, {"family": "Bliuc", "given": "Dana", "initials": "D"}, {"family": "Schmitz", "given": "Daniel", "initials": "D"}, {"family": "Ek", "given": "Weronica E", "initials": "WE"}, {"family": "Skalkidou", "given": "Alkistis", "initials": "A"}, {"family": "Center", "given": "Jacqueline R", "initials": "JR"}, {"family": "Johansson", "given": "\u00c5sa", "initials": "\u00c5"}], "type": "journal article", "published": "2024-11-27", "journal": {"title": "BMJ", "issn": "1756-1833", "volume": "387", "pages": "e078784", "issn-l": "1756-1833"}, "abstract": "To assess the effect of contemporary menopausal hormone therapy on the risk of cardiovascular disease according to the route of administration and combination of hormones.\n\nNationwide register based emulated target trial.\n\nSwedish national registries.\n\n919 614 women aged 50-58 between 2007 and 2020 without hormone therapy use in the previous two years, identified from the Swedish population.\n\n138 nested trials were designed, starting each month from July 2007 until December 2018. Using the prescription registry data for that specific month, women who had not used hormone therapy in the previous two years were assigned to one of eight treatment groups: oral combined continuous, oral combined sequential, oral unopposed oestrogen, oral oestrogen with local progestin, tibolone, transdermal combined, transdermal unopposed oestrogen, or non-initiators of menopausal hormone therapy.\n\nHazard ratios with 95% confidence intervals were estimated for venous thromboembolism, as well as for ischaemic heart disease, cerebral infarction, and myocardial infarction separately and as a composite cardiovascular disease outcome. Treatment effects were estimated by contrasting initiators and non-initiators in observational analogues to \"intention-to-treat\" analyses and continuous users versus never users in \"per protocol\" analyses.\n\nA total of 77 512 women were initiators of any menopausal hormone therapy and 842 102 women were non-initiators. 24 089 women had an event recorded during the follow-up: 10 360 (43.0%) had an ischaemic heart disease event, 4098 (17.0%) had a cerebral infarction event, 4312 (17.9%) had a myocardial infarction event, and 9196 (38.2%) had a venous thromboembolic event. In intention-to-treat analyses, tibolone was associated with an increased risk of cardiovascular disease (hazard ratio 1.52, 95% confidence interval 1.11 to 2.08) compared with non-initiators. Initiators of tibolone or oral oestrogen-progestin therapy had a higher risk of ischaemic heart disease (1.46 (1.00 to 2.14) and 1.21 (1.00 to 1.46), respectively). A higher risk of venous thromboembolism was observed for oral continuous oestrogen-progestin therapy (1.61, 1.35 to 1.92), sequential therapy (2.00, 1.61 to 2.49), and oestrogen-only therapy (1.57, 1.02 to 2.44). Additional results in per protocol analyses showed that use of tibolone was associated with a higher risk of cerebral infarction (1.97, 1.02 to 3.78) and myocardial infarction (1.94, 1.01 to 3.73).\n\nUse of oral oestrogen-progestin therapy was associated with an increased risk of heart disease and venous thromboembolism, whereas the use of tibolone was associated with an increased risk of ischaemic heart disease, cerebral infarction, and myocardial infarction but not venous thromboembolism. These findings highlight the diverse effects of different hormone combinations and administration methods on the risk of cardiovascular disease.", "doi": "10.1136/bmj-2023-078784", "pmid": "39603704", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11600536"}], "notes": [], "created": "2026-08-20T12:01:56.764Z", "modified": "2026-08-20T12:01:56.809Z"}, {"entity": "publication", "iuid": "48b09050406044a7a38ae3ce425be1a1", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/48b09050406044a7a38ae3ce425be1a1.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/48b09050406044a7a38ae3ce425be1a1"}}, "title": "Population-based cohort study of oral contraceptive use and risk of depression.", "authors": [{"family": "Johansson", "given": "T", "initials": "T", "orcid": "0000-0003-1043-7065", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/d4005242bc4c45f6a0899226560837f8.json"}}, {"family": "Vinther Larsen", "given": "S", "initials": "S"}, {"family": "Bui", "given": "M", "initials": "M"}, {"family": "Ek", "given": "W E", "initials": "WE"}, {"family": "Karlsson", "given": "T", "initials": "T"}, {"family": "Johansson", "given": "\u00c5", "initials": "\u00c5"}], "type": "journal article", "published": "2023-06-12", "journal": {"title": "Epidemiol Psychiatr Sci", "issn": "2045-7979", "volume": "32", "pages": "e39", "issn-l": null}, "abstract": "Research on the effect of oral contraceptive (OC) use on the risk of depression shows inconsistent findings, especially in adult OC users. One possible reason for this inconsistency is the omission of women who discontinue OCs due to adverse mood effects, leading to healthy user bias. To address this issue, we aim to estimate the risk of depression that is associated with the initiation of OCs as well as the effect of OC use on lifetime risk of depression.\n\nThis is a population-based cohort study based on data from 264,557 women from the UK Biobank. Incidence of depression was addressed via interviews, inpatient hospital or primary care data. The hazard ratio (HR) between OC use and incident depression was estimated by multivariable Cox regression with OC use as a time-varying exposure. To validate causality, we examined familial confounding in 7,354 sibling pairs.\n\nWe observed that the first 2 years of OC use were associated with a higher rate of depression compared to never users (HR = 1.71, 95% confidence interval [CI]: 1.55-1.88). Although the risk was not as pronounced beyond the first 2 years, ever OC use was still associated with an increased lifetime risk of depression (HR = 1.05, 95% CI: 1.01-1.09). Previous OC use were associated with a higher rate of depression compared to never users, with adolescent OC users driving the increased hazard (HR = 1.18, 95% CI: 1.12-1.25). No significant association were observed among adult OC users who had previously used OCs (HR = 1.00, 95% CI: 0.95-1.04). Notably, the sibling analysis provided further evidence for a causal effect of OC use on the risk of depression.\n\nOur findings suggest that the use of OCs, particularly during the first 2 years, increases the risk of depression. Additionally, OC use during adolescence might increase the risk of depression later in life. Our results are consistent with a causal relationship between OC use and depression, as supported by the sibling analysis. This study highlights the importance of considering the healthy user bias as well as family-level confounding in studies of OC use and mental health outcomes. Physicians and patients should be aware of this potential risk when considering OCs, and individualized risk-benefit assessments should be conducted.", "doi": "10.1017/S2045796023000525", "pmid": "37303201", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC10294242"}, {"db": "pii", "key": "S2045796023000525"}], "notes": [], "created": "2026-08-20T08:08:09.969Z", "modified": "2026-08-20T08:08:10.064Z"}, {"entity": "publication", "iuid": "b73b4aa99d6147469278a0f4e9f0fb6f", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/b73b4aa99d6147469278a0f4e9f0fb6f.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/b73b4aa99d6147469278a0f4e9f0fb6f"}}, "title": "Oral Contraceptives, Hormone Replacement Therapy, and Stroke Risk.", "authors": [{"family": "Johansson", "given": "Therese", "initials": "T", "orcid": "0000-0003-1043-7065", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/d4005242bc4c45f6a0899226560837f8.json"}}, {"family": "Fowler", "given": "Philip", "initials": "P"}, {"family": "Ek", "given": "Weronica E", "initials": "WE", "orcid": "0000-0003-2194-496X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8172f56f87554938a75cef7505f8603e.json"}}, {"family": "Skalkidou", "given": "Alkistis", "initials": "A", "orcid": "0000-0002-4935-7532", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/882f68bd159a46e5999dedb151bd7ea4.json"}}, {"family": "Karlsson", "given": "Torgny", "initials": "T", "orcid": "0000-0001-8095-6149", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c8b2bb8ecf4545ad946ae2203c870282.json"}}, {"family": "Johansson", "given": "\u00c5sa", "initials": "\u00c5", "orcid": "0000-0002-2915-4498", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a0bac3e1e64949fcbac4b4d839e1144d.json"}}], "type": "journal article", "published": "2022-10-00", "journal": {"title": "Stroke", "issn": "1524-4628", "volume": "53", "issue": "10", "pages": "3107-3115", "issn-l": "0039-2499"}, "abstract": "Millions of women worldwide use exogenous hormones as oral contraceptives or hormone replacement therapy. Still, time-dependent and long-term consequences of exogenous hormones on stroke risk remains unclear.\n\nWe examined the association between self-reported oral contraceptive and hormone replacement therapy use and stroke risk in 257 194 women from the UK Biobank, born between 1939 and 1970. Outcomes included any type of stroke, ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Exposures were analyzed as time-varying variables in Cox regression models.\n\nDuring first year of oral contraceptive use, an increased event rate of any stroke was observed (hazard ratio [HR], 2.49 [95% CI, 1.44-4.30]), while the hazards were found to be comparable during remaining years of use (HR, 1.00 [95% CI, 0.86-1.14]), compared with nonusers. Similarly, first year of hormone replacement therapy use was associated with higher hazard rates of any stroke (HR, 2.12 [95% CI, 1.66-2.70]), as well as cause-specific stroke, including ischemic stroke (HR, 1.93 [95% CI, 1.05-3.57]) and subarachnoid hemorrhage (HR, 2.17 [95% CI, 1.25-3.78]), which remained increased for any stroke during remaining years of use (HR, 1.18 [95% CI, 1.05-1.31]), and after discontinuation (HR, 1.16 [95% CI, 1.02-1.32]).\n\nOral contraceptive use and hormone replacement therapy were associated with an increased risk of stroke, especially during the first year of use, possibly due to immediate changes in hemostatic balance. This study provides new insights on the effects of hormone exposure on stroke risk and provide evidence of not only an overall risk but also a pronounced effects seen in the beginning of treatment.", "doi": "10.1161/STROKEAHA.121.038659", "pmid": "35735009", "labels": [], "xrefs": [], "notes": [], "created": "2026-08-20T12:16:19.528Z", "modified": "2026-08-20T12:16:19.615Z"}, {"entity": "publication", "iuid": "640c7c9b41264e4592e88f52f9e5ef26", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/640c7c9b41264e4592e88f52f9e5ef26.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/640c7c9b41264e4592e88f52f9e5ef26"}}, "title": "Using genotyping and whole-exome sequencing data to improve genetic risk prediction in deep venous thrombosis", "authors": [{"family": "Lo Faro", "given": "Valeria", "initials": "V", "orcid": "0000-0003-4931-7327", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a3ed8bac701d4dcd9551e4cdfdfba5d7.json"}}, {"family": "Johansson", "given": "Therese", "initials": "T", "orcid": "0000-0003-1043-7065", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/d4005242bc4c45f6a0899226560837f8.json"}}, {"family": "H\u00f6glund", "given": "Julia", "initials": "J", "orcid": "0000-0001-8061-3947", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/bca098a65a67444899762a18f654f447.json"}}, {"family": "Hadizadeh", "given": "Fatemeh", "initials": "F", "orcid": "0000-0002-9855-7610", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8d0b9d82968f456798ee9dd0b1dfa7d9.json"}}, {"family": "Johansson", "given": "\u00c5sa", "initials": "\u00c5", "orcid": "0000-0002-2915-4498", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a0bac3e1e64949fcbac4b4d839e1144d.json"}}], "type": "posted-content", "published": "2022-04-27", "journal": {"issn-l": null}, "abstract": null, "doi": "10.1101/2022.04.24.22274229", "pmid": null, "labels": [], "xrefs": [], "notes": [], "created": "2026-08-20T10:11:00.559Z", "modified": "2026-08-20T10:11:00.678Z"}, {"entity": "publication", "iuid": "fa0b5a942cac4aa9a1081b3d37781d5a", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/fa0b5a942cac4aa9a1081b3d37781d5a.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/fa0b5a942cac4aa9a1081b3d37781d5a"}}, "title": "Characterization of the human ABO genotypes and their association to common inflammatory and cardiovascular diseases in the UK Biobank.", "authors": [{"family": "H\u00f6glund", "given": "Julia", "initials": "J", "orcid": "0000-0001-8061-3947", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/bca098a65a67444899762a18f654f447.json"}}, {"family": "Karlsson", "given": "Torgny", "initials": "T", "orcid": "0000-0001-8095-6149", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c8b2bb8ecf4545ad946ae2203c870282.json"}}, {"family": "Johansson", "given": "Therese", "initials": "T", "orcid": "0000-0003-1043-7065", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/d4005242bc4c45f6a0899226560837f8.json"}}, {"family": "Ek", "given": "Weronica E", "initials": "WE", "orcid": "0000-0003-2194-496X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8172f56f87554938a75cef7505f8603e.json"}}, {"family": "Johansson", "given": "\u00c5sa", "initials": "\u00c5", "orcid": "0000-0002-2915-4498", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a0bac3e1e64949fcbac4b4d839e1144d.json"}}], "type": "journal article", "published": "2021-11-01", "journal": {"title": "Am. J. Hematol.", "issn": "1096-8652", "volume": "96", "issue": "11", "pages": "1350-1362", "issn-l": "0361-8609"}, "abstract": "The ABO gene contains three major alleles that encodes different antigens; A, B, and O, which determine an individual's blood group. Previous studies have primarily focused on identifying associations between ABO blood groups and diseases risk. Here, we sought to test for association between ABO genotypes (OO, OA, AA; OB, BB, and AB) and a large set of common inflammatory and cardiovascular diseases in UK Biobank as well as disease-related protein biomarkers in NSPHS. We first tested for association by conducting a likelihood ratio test, testing whether ABO contributed significantly to the risk for 24 diseases, and 438 plasma proteins. For phenotypes with FDR < 0.05, we tested for pair-wise differences between genetically determined ABO genotypes using logistic or linear regression. Our study confirmed previous findings of a strong association between ABO and cardiovascular disease, identified associations for both type 1 and type 2 diabetes, and provide additional evidence of significant differences between heterozygous and homozygous allele carriers for pulmonary embolism, deep vein thrombosis, but also for von Willebrand factor levels. Furthermore, the results indicated an additive effect between genotypes, even between the two most common A subgroups, A1 and A2. Additionally, we found that ABO contributed significantly to 39 plasma proteins, of which 23 have never been linked to the ABO locus before. These results show the need of incorporating ABO genotype information in the consultation and management of patients at risk, rather than classifying patients into blood groups.", "doi": "10.1002/ajh.26307", "pmid": "34329492", "labels": [], "xrefs": [], "notes": [], "created": "2026-08-20T06:28:27.189Z", "modified": "2026-08-20T06:28:27.447Z"}]}